NCT05980806Phase 2Recruiting

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Study sponsor: Karyopharm Therapeutics Inc · KPTI

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-06Estimated
Enrollment · participants58Estimated
Source updated2026-02-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of Participants with Spleen Volume Reduction 35 (SVR35) at Week 24.. After: Measure: Proportion of Participants with Spleen Volume Reduction ≥35% (SVR35) at Week 24.

Planned enrollment decreased by 60 participants

Before: 118 participants (planned). After: 58 participants (planned).

Primary completion date changed

Before: Apr 2026. After: Jun 2027.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview